ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Status:
Not yet recruiting
Trial end date:
2026-04-04
Target enrollment:
Participant gender:
Summary
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult
Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic
Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with
recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery
and/or radiation therapy.